PBE Invesco Biotechnology & Genome ETF
Quote as of Oct 09, 2026 19:59 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 94.25 | Day Range | 94.43 – 97.15 |
| 52-Week Range | 70.01 – 98.82 | Volume | 2.71K |
| Avg Volume | 22.14K | AUM | $409.9M (Oct 10, 2026) |
| Expense Ratio | 0.59% | Yield (TTM) | 1.37% |
| NAV | 94.23 | Premium/Discount | +3.01% indicative |
| Inception | Jun 23, 2005 | Holdings | 31 |
| Issuer | Invesco | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 46137V787 | ISIN | US46137V7872 |
| Management | Not stated in source data | ||
About this ETF
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +2.43% | +6.29% | +22.91% | +17.95% | +35.43% | +19.07% | +5.47% | +9.12% | +9.16% |
| Total return | +2.43% | +6.29% | +24.09% | +19.22% | +37.58% | +19.95% | +5.94% | +9.48% | +9.45% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.59% | Annual cost of a $10,000 investment | $59.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 34 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Illumina Inc | ILMN | 6.29% | 95.40K | $26.5M |
| 2 | Natera Inc | NTRA | 6.05% | 63.74K | $25.5M |
| 3 | Biogen Inc | BIIB | 5.20% | 97.22K | $21.9M |
| 4 | Gilead Sciences Inc | GILD | 5.17% | 144.27K | $21.8M |
| 5 | Amgen Inc | AMGN | 4.77% | 48.53K | $20.1M |
| 6 | Vertex Pharmaceuticals Inc | VRTX | 4.69% | 38.82K | $19.8M |
| 7 | Royalty Pharma PLC | RPRX | 4.66% | 345.80K | $19.7M |
| 8 | Regeneron Pharmaceuticals Inc | REGN | 4.55% | 25.75K | $19.2M |
| 9 | Moderna Inc | MRNA | 3.93% | 73.72K | $16.6M |
| 10 | Novavax Inc | NVAX | 3.75% | 1.24M | $15.8M |
| 11 | United Therapeutics Corp | UTHR | 2.94% | 22.58K | $12.4M |
| 12 | Exelixis Inc | EXEL | 2.93% | 206.41K | $12.4M |
| 13 | QIAGEN NV | QGEN | 2.88% | 268.21K | $12.2M |
| 14 | Veracyte Inc | VCYT | 2.85% | 265.84K | $12.0M |
| 15 | Halozyme Therapeutics Inc | HALO | 2.80% | 107.09K | $11.8M |
| 16 | TG Therapeutics Inc | TGTX | 2.77% | 211.25K | $11.7M |
| 17 | Repligen Corp | RGEN | 2.65% | 64.44K | $11.2M |
| 18 | Protagonist Therapeutics Inc | PTGX | 2.65% | 77.74K | $11.2M |
| 19 | Sarepta Therapeutics Inc | SRPT | 2.62% | 618.79K | $11.0M |
| 20 | Neurocrine Biosciences Inc | NBIX | 2.58% | 76.34K | $10.9M |
| 21 | Vericel Corp | VCEL | 2.57% | 270.88K | $10.9M |
| 22 | PTC Therapeutics Inc | PTCT | 2.44% | 159.35K | $10.3M |
| 23 | Legend Biotech Corp | LEGN | 2.43% | 549.65K | $10.2M |
| 24 | BioCryst Pharmaceuticals Inc | BCRX | 2.41% | 1.19M | $10.2M |
| 25 | Incyte Corp | INCY | 2.41% | 90.25K | $10.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.37% | Paid (last 12 months) | $1.3314 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 21, 2026 | Last payment | $0.0187 (Sep 25, 2026) |
| Growth 1Y | +233.94% | Growth 3Y / 5Y (ann.) | +355.70% / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 21, 2026 | Sep 21, 2026 | Sep 25, 2026 | $0.0187 |
| Jun 22, 2026 | Jun 22, 2026 | Jun 26, 2026 | $0.8106 |
| Mar 23, 2026 | Mar 23, 2026 | Mar 27, 2026 | $0.0824 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $0.4197 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 26, 2025 | $0.2341 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.1305 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 28, 2025 | $0.0341 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.0082 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 22, 2024 | $0.0242 |
| Jun 20, 2023 | Jun 21, 2023 | Jun 23, 2023 | $0.0141 |
| Mar 23, 2020 | Mar 24, 2020 | Mar 31, 2020 | $0.0290 |
| Sep 24, 2018 | Sep 25, 2018 | Sep 28, 2018 | $0.0021 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 19.37% / 20.59% | Sharpe 1Y / 3Y | 2.01 / 0.901 |
| Max drawdown 1Y / 3Y | -11.72% / -22.42% | Sortino 1Y | 3.25 |
| Beta vs S&P 500 (3Y) | 0.765 | Correlation vs S&P 500 (1Y) | 0.411 |
| Downside deviation 1Y | 11.97% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 2.71K | Average volume | 22.14K |
| AUM | $409.9M | Premium/Discount | +3.01% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$2.5M | -0.61% | $412.4M → $409.9M |
| 1 Month | -$20.1M | -4.86% | $412.3M → $409.9M |
| 1 Week | -$12.4M | -3.00% | $414.4M → $409.9M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for PBE
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.